News

Biopharma news, November 18, 2026

4 stories

In this digest: Approval 2 · Pivotal readout 1 · Licensing & partnership 1

Top stories

  1. ApprovalBetta Pharmaceuticals

    Gevalka Approved in EU

    The European Commission approved Gevalka for adults with ALK-positive advanced non-small cell lung cancer. The approval was based on the phase 3 eXalt3 study, in which median progression-free survival was 25.8 months with ensartinib versus 12.7 months in the control group. Betta and its subsidiary Xcovery developed ensartinib, which has also been approved in China and the United States; an exclusive licensing agreement with Mankind Pharma covers India.

    Source types: Press release

  2. Pivotal readout

    Dayvigo Korea Launch Planned

    A sleep specialist reported that Dayvigo maintained improvements in insomnia outcomes for one year in SUNRISE 2, without evidence of tolerance, rebound insomnia or withdrawal symptoms after discontinuation.

    Read more about Dayvigo Korea Launch Planned

    In SUNRISE 1, Dayvigo shortened time to sleep onset more than extended-release zolpidem in older adults. Other studies discussed nighttime balance, next-morning driving and breathing safety. South Korea approved Dayvigo in June for adults with difficulty falling or staying asleep. Eisai Korea plans a late-November launch and will co-promote it with SK Chemicals.

    Source types: News article

  3. Licensing & partnershipPfizer, Starna Therapeutics

    Pfizer Licenses Starna CAR-T Programs

    Pfizer licensed three pre-IND in vivo CAR-T programs for autoimmune diseases from Starna Therapeutics, with exclusive rights outside Greater China.

    Read more about Pfizer Licenses Starna CAR-T Programs

    Starna will receive $330 million upfront and is eligible for up to $2.3 billion in development and commercial milestones, plus royalties. Pfizer will lead development outside Greater China, plans to manufacture initial clinical trial product in the United States, and has options to expand its territorial rights.

    Source types: Press release

News in brief

  1. Approval

    FDA Clears Masimo smartSedLine

    Read more about FDA Clears Masimo smartSedLine

    Masimo received FDA 510(k) clearance for smartSedLine, a brain function monitoring solution for use during anesthesia. Its enhanced Patient State Index algorithm is designed to respond faster during induction and provide more stable readings under low EEG power. The new module and sensor work with compatible monitors, including Masimo Root, and can be used alongside O3 Regional Oximetry.

    Source types: Press release

All digests

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call